Participated · Equity · May 2026

Mentari’s lead programs are MT-001, an anti-PACAP monoclonal antibody slated for first-in-human regulatory filings in mid-2026, and MT-002, an anti-CGRP x PACAP bispecific antibody expected to enter regulatory filings in the first quarter of 2027. The programs were discovered by Paragon Therapeutics and have shown strong in vitro potency and favorable pharmacokinetic profiles in preclinical studies. The therapies are designed to target complementary migraine pathways and address patients who experience limited benefit from currently approved anti-CGRP treatments. Mentari announced a $290 million private placement that it says will fund operations through 2028 and entered an all-stock merger agreement with InMed Pharmaceuticals to gain public market infrastructure. Following the transaction the combined company is expected to trade on the Nasdaq Capital Market and have a pro forma equity value of approximately $421.4 million, with pre-merger InMed shareholders holding about 1.51% of the combined company. The company and merger parties expect to accelerate development timelines and pursue regulatory filings according to the stated milestones.

Participated · Series B · Jan 2026

Mirador Therapeutics is focused on delivering first- and best-in-class therapeutics for Crohn’s disease, ulcerative colitis, rheumatoid arthritis, idiopathic pulmonary fibrosis, and other immuno-fibrotic conditions. Its Mirador360 (M360) discovery and development engine combines more than 2.5 million patient profiles with advanced machine learning to uncover novel targets, stratify patients, and design rational drug combinations. In less than two years, the company has advanced multiple clinical-stage assets and is pursuing a parallel development strategy that aims to generate ten or more clinical readouts by the end of 2027. Management positions the approach as a step-change over incremental monotherapies, seeking to redefine precision medicine in immunology and inflammation. Mirador has raised over $650 million since launching in March 2024, enabling it to fund proof-of-concept studies across its current portfolio and add new pipeline candidates. The company operates with an emphasis on capital efficiency and disciplined execution to sustain momentum. Mirador is headquartered in San Diego, California.

Participated · Series F · Jan 2026

Parabilis Medicines is pioneering stabilized, cell-penetrant α-helical peptides, called Helicons™, to modulate intracellular proteins that small molecules and antibodies cannot reach. Its lead candidate, FOG-001 (zolucatetide), directly inhibits the β-catenin:TCF interaction within the Wnt/β-catenin pathway and has shown meaningful single-agent activity across five tumor types, including desmoid tumors and adamantinomatous craniopharyngioma. The drug has U.S. FDA Fast Track Designation for desmoid tumors and is moving toward a registrational trial while additional data in hepatocellular carcinoma and familial adenomatous polyposis are forthcoming. Beyond FOG-001, Parabilis is advancing preclinical Helicon degraders against ERG and allosteric ARON for prostate cancer, demonstrating the broad applicability of its platform. Headquartered in Cambridge, Massachusetts, the company leverages proprietary data, AI- and physics-based algorithms, and more than a decade of laboratory innovation. Financially, Parabilis closed an oversubscribed $305 million Series F round at an increased valuation, positioning it to expand clinical and preclinical programs. No revenue or user metrics have been disclosed, consistent with its clinical-stage status.

Participated · Series D · Mar 2025

Pentera offers an automated security validation platform that launches simulated network attacks to stress-test software and human response. The product, described as "automated security validation," can run safe-by-design mega-attacks while keeping non-security staff unaware. Pentera’s platform identifies specific vulnerabilities, can surface as many as 10,000 alerts and automatically reduces them to six to eight root causes with remediation suggestions. The company incorporates AI considerations into its platform to address evolving attacker and defender tooling. Pentera has grown customers by 200% to 1,100 organizations and expanded ARR by 300% over the last four years. The company is Boston-based and Tel Aviv-founded. Funding will be used for M&A and continued product development, per CEO Amitai Ratzon. Pentera offers an agentless Automated Security Validation (ASV) platform that automates penetration testing and continuous security validation for enterprises. Its platform includes modules such as RansomwareReady™ and Log4Shell validation to test real-world attack paths and prioritize remediation. The company says thousands of security professionals and service providers use its technology and it serves more than 400 enterprise customers. Pentera has grown rapidly since debuting its automated penetration testing technology three years ago and has scaled to a headcount of 150 with plans to double to 300 by the end of 2022. The firm intends to use new funding to expand global operations, broaden its product line, and continue scaling across functions and regions as it pursues an eventual IPO. Pcysys develops PenTera, an Automated Penetration Testing platform that uses algorithms to scan and ethically attack enterprise networks to identify security weaknesses from a threat-facing perspective. The platform runs on-premise or remotely and enables cost-effective remediation by focusing on vulnerabilities involved in a proven “kill-chain,” providing visibility into true cybersecurity posture. Since its market debut in mid-2018 the company has experienced substantial year-over-year revenue growth, serves hundreds of enterprise customers across more than 15 industries, and is used by MSSPs to deliver remote Penetration-Testing-as-a-Service. Pcysys currently has 60 employees worldwide. The company intends to use the new funds to expand its sales and delivery teams in North America, EMEA and Asia Pacific and to continue development of its technology. Founded in November 2015 and led by CEO Amitai Ratzon, Pcysys has raised $40m to date. Pcysys, founded in November 2015 by Arik Liberzon and Arik Faingold and led by CEO Amitai Ratzon since 2018, is a Tel Aviv, Israel–based cyber security risk validation company. It offers the PenTera™ platform, which uses algorithms to scan and ethically penetrate corporate networks with current hacking techniques to prioritize remediation from a threat-facing perspective. The platform helps organizations focus on vulnerabilities that participate in damaging kill-chains rather than chasing thousands of non-exploitable issues. Pcysys has about 50 employees and is approaching 100 paying enterprise customers across 15 verticals in North America, Europe and Israel. The company completed a $10M Series A and has raised $15M to date. It intends to use the additional funding to expand sales and support in North America and EMEA and to further develop its enterprise-grade technology.

Participated · Series D · Sep 2024

eGenesis is a biotechnology company developing human-compatible engineered organs to address the global organ shortage. Its lead product candidate, the donor kidney EGEN-2784, carries three classes of genome edits: knockout of glycan-antigen synthesis genes, insertion of seven human transgenes to modulate rejection pathways, and inactivation of endogenous porcine retroviruses. The company’s EGEN genome engineering and production platform aims to comprehensively address cross-species molecular incompatibilities and viral risk. Proceeds from the $191 million Series D will be used to advance EGEN-2784 to a first-in-human kidney transplant study, advance pipeline programs (including acute liver failure and heart transplant), and scale production. In March 2024 eGenesis announced the world’s first successful porcine kidney transplant in a living patient under an FDA Expanded Access authorization, performed at Massachusetts General Hospital. The company says it is the only firm developing organs that carry all three classes of edits to address organ safety and efficacy. eGenesis develops human-compatible organs, tissues, and cells using gene-editing and genome-engineering to address barriers to xenotransplantation. The company harnesses gene editing technologies to make organs safe and effective for patients in need. Its development pipeline includes lead programs for kidney and islet cell transplants and earlier-stage programs targeting other solid organs. eGenesis intends to use its Series C proceeds to bring lead kidney and islet programs into human proof-of-concept studies, continue development of its proprietary gene-editing platform, and scale GMP production. The company is led by Paul Sekhri, President and Chief Executive Officer. Financially, eGenesis completed a $125m Series C financing in February 2021. eGenesis develops human-compatible organs using gene editing technologies such as CRISPR to overcome virology and immunology hurdles that have impeded xenotransplantation. The company is advancing an initial kidney product toward the clinic while pursuing programs in islet cell, liver, heart, and lung. It intends to use new funding to accelerate its kidney xenotransplant program into the clinic and to support advancement of other xenotransplant programs. eGenesis positions xenotransplantation as a potential solution for a broader organ recipient population and to expand applicability into areas such as cell therapy. The company is led by president and CEO Paul Sekhri and is based in Cambridge, Massachusetts. eGenesis completed a $100M Series B financing to support these efforts. eGenesis uses a CRISPR-based genome editing platform to engineer pig cells and organs intended for safe and effective human transplantation. The company’s core approach includes genomic engineering of pig cells, organ maturation, and eventual organ transplantation. eGenesis positions xenotransplantation as a solution to the severe shortage of transplantable human organs and aims to make it a routine lifesaving medical procedure. Its scientific team includes co-founder and CSO Luhan Yang and Harvard geneticist George Church, plus multiple scientists from Harvard with expertise in genome editing, synthetic biology, and transgenic animals. The company is in early stages of development and is advancing its platform toward delivering transplantable cells, tissues and organs. eGenesis announced a recent financing to support these development efforts.